Bio-Rad Reports Q1 2026 Earnings with Mixed Results
Bio-Rad (BIO) reported Q1 2026 earnings with net sales of $592 million, a 1.1% increase, but currency-neutral sales declined 4.2%. The Life Science and Clinical Diagnostics segments faced challenges, including regional headwinds and the impact of the Middle East conflict. The company's gross margin and operating income also declined compared to the prior year.
Tickers: $BIO
Topics: earnings report financial performance gross margin operating income revenue